Insulet Corporation $PODD Stock Acquired by Brighton Jones LLC

Brighton Jones LLC grew its stake in shares of Insulet Corporation (NASDAQ:PODD) by 85.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,341 shares of the medical instruments supplier’s stock after acquiring an additional 4,292 shares during the period. Brighton Jones LLC’s holdings in Insulet were worth $1,219,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Elevation Wealth Partners LLC raised its stake in shares of Insulet by 115.6% during the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 104 shares during the period. Activest Wealth Management boosted its holdings in Insulet by 186.3% in the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 149 shares during the period. WPG Advisers LLC grew its position in shares of Insulet by 169.3% during the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 171 shares in the last quarter. State of Wyoming grew its position in shares of Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after purchasing an additional 73 shares in the last quarter. Finally, Continuum Advisory LLC purchased a new position in shares of Insulet during the 2nd quarter valued at $46,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Citigroup increased their price objective on Insulet from $150.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Jefferies Financial Group restated a “buy” rating and set a $200.00 target price on shares of Insulet in a research report on Wednesday, November 4th. JPMorgan Chase & Co. upped their target price on Insulet from $152.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday, November 5th. Royal Bank Of Canada raised their price target on Insulet from $160.00 to $180.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Finally, Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a research report on Saturday. Twelve equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Insulet presently has an average rating of “Hold” and an average target price of $185.67.

Insulet Price Performance

PODD stock opened at $148.06 on Wednesday. The firm has a 50 day simple moving average of $142.05 and a two-hundred day simple moving average of $175.32. The stock has a market cap of $10.27 billion, a PE ratio of 24.11, a P/E/G ratio of 1.14 and a beta of 1.06. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.51 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. The firm had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The business’s quarterly revenue was up 19.2% on a year-over-year basis. During the same quarter last year, the company posted $1.24 EPS. On average, analysts predict that Insulet Corporation will post 6.75 EPS for the current fiscal year.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Truist raised its price target to $160 from $153 while maintaining a “hold” rating, implying potential upside from the cited share price. Truist price target
• Positive Sentiment: A separate report said Insulet’s growth characteristics could help it outperform the market, though it did not provide specific new financial guidance. Zacks growth-stock analysis
• Neutral Sentiment: Insulet launched a World Diabetes Day campaign encouraging people with diabetes to prioritize well-being. The initiative may support awareness but does not indicate a direct near-term financial impact. World Diabetes Day campaign
• Neutral Sentiment: A short-interest update reported zero shares sold short and a 0.0-day days-to-cover ratio, despite describing short interest as having increased. The figures therefore do not point to meaningful short-squeeze activity.

Insulet Company Profile

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.